Medication Comparison · Updated March 2026

Zepbound vs Wegovy: Which FDA-Approved Weight Loss GLP-1 Should You Choose?

Zepbound and Wegovy are the only two GLP-1 medications with FDA approval specifically for weight management. They work differently, produce different amounts of weight loss, and cost different amounts. I have been on tirzepatide (the molecule in Zepbound) for over a year and track my results with DEXA scans. This is the comparison I wish I had when I was deciding.

TL;DR

• Zepbound (tirzepatide) produced 20.2% weight loss vs Wegovy’s 13.7% in the direct head-to-head SURMOUNT-5 trial. That is roughly 47% more weight loss.
• Wegovy has cardiovascular data from the SELECT trial showing a 20% reduction in heart attacks, strokes, and cardiovascular death. Zepbound does not have equivalent published data yet.
• Zepbound brand price is ~$1,060/mo. Lilly offers a direct-pay option at $399-$549/mo. Wegovy brand price is ~$1,349/mo.
• Wegovy has better insurance coverage because it has been on the market longer (approved 2021 vs 2023 for Zepbound).
• Wegovy is now available as an oral pill (FDA-approved in 2025). Zepbound is injection-only.

Quick Comparison Table

Active Ingredient and Mechanism

Zepbound and Wegovy are fundamentally different drugs. They share the GLP-1 pathway, but that is where the similarity ends.

Zepbound contains tirzepatide, a dual GIP/GLP-1 receptor agonist made by Eli Lilly. It activates two hormone receptors: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Think of it as two separate appetite and metabolism signals firing at once. The GIP component appears to enhance fat metabolism beyond what GLP-1 alone can do.

Wegovy contains semaglutide, a GLP-1 receptor agonist made by Novo Nordisk. It targets one hormone receptor (GLP-1), which slows gastric emptying, reduces hunger signals to the brain, and improves insulin sensitivity.

Both drugs are injected once weekly. The key structural difference is that tirzepatide’s dual mechanism is widely believed to explain its greater weight loss results. For more on how these molecules compare, see our full four-way comparison.

FDA Status

Both Zepbound and Wegovy are FDA-approved specifically for chronic weight management in adults with a BMI of 30 or higher (or 27+ with at least one weight-related condition like hypertension, type 2 diabetes, or dyslipidemia).

• Wegovy was approved in June 2021. It has been on the market longer, which matters for insurance formulary placement.
• Zepbound was approved in November 2023. It entered the market later, so insurance coverage is still catching up.

Both are on-label for weight loss. Neither requires a diabetes diagnosis. That said, insurance coverage differs significantly between the two (more on that below).

Weight Loss Data: SURMOUNT-5 Head-to-Head

This is the comparison that matters most, because we have a direct head-to-head trial.

The SURMOUNT-5 trial randomized adults with obesity (no diabetes) to either tirzepatide (up to 15 mg) or semaglutide (up to 2.4 mg) for 72 weeks. The results:

• Tirzepatide group: 20.2% body weight loss
• Semaglutide group: 13.7% body weight loss

For a 250-pound person, that translates to roughly 50.5 pounds lost on Zepbound versus 34.3 pounds on Wegovy. That is a 16-pound difference between the two groups on average.

The tirzepatide group also saw a higher percentage of participants reaching meaningful weight loss thresholds. Over 30% of the tirzepatide group lost more than 25% of their body weight. In the semaglutide group, that number was significantly lower.

I have been tracking my own DEXA scans on tirzepatide, and the fat loss has been consistent month over month. The data from SURMOUNT-5 matches what I have seen in practice. Tirzepatide is the stronger drug for pure weight loss. That said, Wegovy’s 13.7% is still substantial. Losing 13-14% of your body weight is life-changing for most people.

Dosing Schedule

Both are weekly injections, but the dose ranges are different.

Zepbound (tirzepatide):

• Starting dose: 2.5 mg/week for 4 weeks
• Then: 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg (each for 4+ weeks)
• Max dose: 15 mg/week

Wegovy (semaglutide) injectable:

• Starting dose: 0.25 mg/week for 4 weeks
• Then: 0.5 mg, 1 mg, 1.7 mg, 2.4 mg (each for 4 weeks)
• Max dose: 2.4 mg/week

Wegovy oral pill (approved 2025):

• Taken daily (not weekly)
• Dose range: up to 25 mg/day
• No injection required

The Wegovy pill is a real differentiator. If needles are a barrier for you, oral semaglutide is now an option. We wrote a full breakdown of the Wegovy pill vs injection if you want the details on how they compare.

Side Effects

The side effect profiles overlap significantly. Both drugs cause GI issues, especially during dose escalation.

Most common side effects for both:

• Nausea (most reported, usually peaks 1-2 weeks after each dose increase)
• Diarrhea
• Constipation
• Vomiting
• Decreased appetite
• Injection site reactions

Key difference from SURMOUNT-5: The discontinuation rate due to GI side effects was lower for tirzepatide (2.7%) than semaglutide (5.6%). This surprised a lot of people, because tirzepatide at higher doses was expected to cause more GI issues. In practice, the dual mechanism may actually be easier on the gut than high-dose semaglutide.

From my own experience on tirzepatide, the nausea was most noticeable during the first week at each new dose. By week 2-3, it settled down. Eating smaller meals and avoiding greasy food helped the most. For a full month-by-month breakdown of what to expect, see our GLP-1 side effects guide.

Serious side effects (rare, both drugs): Pancreatitis, gallbladder issues, thyroid C-cell tumor warnings (from rodent studies). Both carry a boxed warning about medullary thyroid carcinoma risk and are contraindicated if you have a personal or family history of MTC or MEN2.

Cardiovascular Data

This is where Wegovy has an edge that Zepbound cannot match yet.

The SELECT trial studied semaglutide 2.4 mg (the same dose as Wegovy) in over 17,600 adults with obesity and established cardiovascular disease. The results: a 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) over a median follow-up of 40 months.

This is a big deal. No other GLP-1 weight loss medication has published equivalent cardiovascular outcome data. Zepbound’s parent trial program (SURPASS-CVOT) is ongoing, but results are not yet available.

If you have existing heart disease or significant cardiovascular risk factors, the SELECT data gives Wegovy a meaningful advantage. This is worth discussing with your doctor.

Cost Comparison

Zepbound is about $290 cheaper per month at list price. Lilly’s direct-pay program through LillyDirect makes self-pay more predictable at $399-$549 depending on dose.

Wegovy’s list price is higher, but it tends to be on more insurance formularies because it has been approved longer. If your insurance covers Wegovy, your actual out-of-pocket cost could be much lower than Zepbound’s self-pay price.

For a full breakdown of the cheapest ways to access both drugs, see our cheapest GLP-1 online guide.

Insurance Coverage

Wegovy has broader coverage. It was approved in 2021, and the SELECT cardiovascular data gave insurers an additional reason to add it to formularies. Many commercial plans and some state Medicaid programs now cover Wegovy.

Zepbound coverage is growing but more limited. Approved in late 2023, it has not been on formularies as long. Some large employer plans and a few state programs cover it, but many still exclude it.

Medicare does not cover either for weight loss. This may change (legislation has been introduced), but as of early 2026, neither Zepbound nor Wegovy is covered under Medicare Part D for weight management. See our GLP-1 insurance coverage guide for tips on getting approved.

Choose Zepbound If…

• Maximum weight loss is your top priority. The SURMOUNT-5 data is clear: tirzepatide produces significantly more weight loss than semaglutide.
• You can access it affordably. Whether through insurance, LillyDirect’s self-pay, or compounded tirzepatide.
• You have tried semaglutide and plateaued. Some people switch from Wegovy to Zepbound and see renewed progress. The dual mechanism may work better for certain people.
• You are okay with injections. Zepbound is injection-only (no oral option).

Choose Wegovy If…

• You have cardiovascular risk factors. The SELECT trial data is meaningful. A 20% reduction in heart attacks, strokes, and cardiovascular death is a real clinical benefit.
• Your insurance covers it but not Zepbound. A covered Wegovy prescription at $25-$50/mo beats an uncovered Zepbound at $1,060/mo.
• You want the oral pill option. The Wegovy pill (approved 2025) removes the needle barrier entirely. See our pill vs injection guide.
• You prefer a longer track record. Semaglutide has been on the market since 2017 (as Ozempic). More long-term real-world data exists.

Frequently Asked Questions

Can I switch from Wegovy to Zepbound (or vice versa)?

Yes. Switching between semaglutide and tirzepatide is common. Your provider will typically restart you at the lowest dose of the new medication and titrate up, because they work on different receptors. Do not try to dose-match between the two drugs on your own. Let your prescriber handle the transition.

Is Zepbound better than Wegovy for everyone?

No. Zepbound produces more average weight loss in clinical trials, but individual responses vary. Some people respond very well to semaglutide and see weight loss at or above the tirzepatide averages. Others respond better to tirzepatide. If cost, insurance, or cardiovascular health is a priority, Wegovy may be the better choice for your specific situation.

Does Medicare cover Zepbound or Wegovy?

Not for weight management as of early 2026. Medicare Part D currently excludes anti-obesity medications. Legislation to change this has been introduced in Congress, but nothing has passed yet. If you have Medicare and type 2 diabetes, you may be able to get Mounjaro (tirzepatide for diabetes) or Ozempic (semaglutide for diabetes) covered instead.

What about compounded versions?

Compounded tirzepatide and compounded semaglutide are available through telehealth providers at significantly lower cost ($149-$399/mo). These contain the same active ingredients but are produced by compounding pharmacies rather than Eli Lilly or Novo Nordisk. See our compounded vs brand-name guide for the full breakdown on safety, legality, and quality differences.

Which one has fewer side effects?

In the SURMOUNT-5 head-to-head trial, the discontinuation rate due to GI side effects was actually lower for tirzepatide (2.7%) compared to semaglutide (5.6%). Both drugs cause nausea, diarrhea, and constipation, but the data suggests tirzepatide may be slightly better tolerated at equivalent clinical doses.

Last updated: March 2026. Pricing and availability may change. This article is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting any medication.